​

Collegium Pharmaceutical (COLL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Collegium Pharmaceutical Revenue Highlights

Latest Revenue (Y)

$780.57M

Latest Revenue (Q)

$209.36M

Main Segment (Y)

Belbuca

Collegium Pharmaceutical Revenue by Period

Collegium Pharmaceutical Revenue by Year

DateRevenueChange
2025-12-31$780.57M23.62%
2024-12-31$631.45M11.41%
2023-12-31$566.77M22.17%
2022-12-31$463.93M67.56%
2021-12-31$276.87M-10.69%
2020-12-31$310.02M4.49%
2019-12-31$296.70M5.81%
2018-12-31$280.41M884.73%
2017-12-31$28.48M1564.29%
2016-12-31$1.71M100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Collegium Pharmaceutical generated $780.57M in revenue during NA 2025, up 23.62% compared to the previous quarter, and up 251.78% compared to the same period a year ago.

Collegium Pharmaceutical Revenue by Quarter

DateRevenueChange
2025-09-30$209.36M11.36%
2025-06-30$188.00M5.76%
2025-03-31$177.76M-2.30%
2024-12-31$181.95M14.22%
2024-09-30$159.30M9.65%
2024-06-30$145.28M0.24%
2024-03-31$144.92M-3.22%
2023-12-31$149.75M9.54%
2023-09-30$136.71M0.86%
2023-06-30$135.55M-6.37%
2023-03-31$144.77M11.69%
2022-12-31$129.62M2.05%
2022-09-30$127.01M2.80%
2022-06-30$123.55M47.52%
2022-03-31$83.75M206.09%
2021-12-31$27.36M-65.30%
2021-09-30$78.84M-4.94%
2021-06-30$82.94M-5.45%
2021-03-31$87.72M15.01%
2020-12-31$76.27M-3.67%
2020-09-30$79.18M1.43%
2020-06-30$78.06M2.02%
2020-03-31$76.51M3.11%
2019-12-31$74.20M1.73%
2019-09-30$72.94M-2.80%
2019-06-30$75.04M0.70%
2019-03-31$74.52M1.48%
2018-12-31$73.43M4.63%
2018-09-30$70.18M-3.95%
2018-06-30$73.06M14.61%
2018-03-31$63.75M490.60%
2017-12-31$10.79M-9.67%
2017-09-30$11.95M235.67%
2017-06-30$3.56M63.90%
2017-03-31$2.17M66.69%
2016-12-31$1.30M219.36%
2016-09-30$408.00K100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31--

Collegium Pharmaceutical generated $209.36M in revenue during Q3 2025, up 11.36% compared to the previous quarter, and up 144.11% compared to the same period a year ago.

Collegium Pharmaceutical Revenue Breakdown

Collegium Pharmaceutical Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Xtampza ER$199.31M$191.33M$177.37M$138.80M$103.71M
Belbuca$221.65M$211.27M$182.09M$126.46M-
Nucynta ER$80.98M$75.77M$82.65M$72.42M$70.94M
Nucynta IR$115.31M$100.74M$108.15M$112.06M$102.22M
Symproic-$15.10M$16.50M$12.27M-
Other---$1.93M-
Nucynta Products----$173.16M

Collegium Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 25: Belbuca (35.91%), Xtampza ER (32.29%), Nucynta IR (18.68%), and Nucynta ER (13.12%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Belbuca$59.14M$58.26M$52.60M$51.66M$107.41M$53.20M$50.66M$94.75M$43.14M$44.21M$42.05M$38.80M$42.30M$3.31M------
Nucynta ER$18.54M$22.81M$19.95M$19.69M$36.81M$19.77M$19.19M$42.35M$19.17M$21.14M$18.95M$17.13M$17.08M$19.26M$8.73M-----
Xtampza ER$48.58M$50.48M$52.60M$47.64M$96.03M$49.49M$45.81M$88.26M$41.24M$47.87M$35.24M$38.86M$33.19M$31.52M------
Nucynta IR$29.41M$31.99M$26.50M$27.42M$49.42M$25.36M$25.96M$52.09M$28.16M$27.90M$28.89M$27.27M$26.55M$29.34M$13.37M-----
Symproic-$4.03M$3.72M$2.81M$8.29M$3.52M$3.30M$9.01M$3.84M$3.65M$4.53M$3.58M$3.86M$300.00K------
Other----------$320.00K$1.15M$458.00K-------
Elyxyb-----------$218.00K$109.00K$25.00K------
Xtampza---------------$30.02M$33.02M$35.41M$30.79M$32.13M
Nucynta Er---------------$19.74M$20.68M$21.79M$16.20M$17.05M
Nucynta Ir---------------$29.09M$29.24M$30.53M$29.27M$30.00M
Nucynta---------------$48.83M$49.92M$52.31M$45.48M$47.05M

Collegium Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Belbuca (37.99%), Xtampza ER (31.21%), Nucynta IR (18.89%), and Nucynta ER (11.91%).

Collegium Pharmaceutical Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GDRXGoodRx$792.32M$196.03M
COLLCollegium Pharmaceutical$780.57M$209.36M
PCRXPacira BioSciences$726.41M$181.10M
AMPHAmphastar Pharmaceuticals$719.89M$191.84M
MDXGMiMedx Group$418.63M$113.72M
INVAInnoviva$411.33M$100.28M
DVAXDynavax$277.25M$95.44M
CRONCronos Group$193.36M$48.83M
NKTRNektar Therapeutics$98.43M$11.79M
ATAIAtai Beckley N.V-$749.00K
PLSEPulse Biosciences--

COLL Revenue FAQ

What is Collegium Pharmaceutical’s yearly revenue?

Collegium Pharmaceutical's yearly revenue for 2025 was $780.57M, representing an increase of 23.62% compared to 2024. The company's yearly revenue for 2024 was $631.45M, representing an increase of 11.41% compared to 2023. COLL's yearly revenue for 2023 was $566.77M, representing an increase of 22.17% compared to 2022.

What is Collegium Pharmaceutical’s quarterly revenue?

Collegium Pharmaceutical's quarterly revenue for Q3 2025 was $209.36M, a 11.36% increase from the previous quarter (Q2 2025), and a 31.42% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $188M, a 5.76% increase from the previous quarter (Q1 2025), and a 29.41% increase year-over-year (Q2 2024). COLL's quarterly revenue for Q1 2025 was $177.76M, a -2.30% decrease from the previous quarter (Q4 2024), and a 22.66% increase year-over-year (Q1 2024).

What is Collegium Pharmaceutical’s revenue growth rate?

Collegium Pharmaceutical's revenue growth rate for the last 3 years (2023-2025) was 37.72%, and for the last 5 years (2021-2025) was 181.93%.

What are Collegium Pharmaceutical’s revenue streams?

Collegium Pharmaceutical's revenue streams in c 25 are Xtampza ER, Belbuca, Nucynta ER, and Nucynta IR. Xtampza ER generated $199.31M in revenue, accounting 32.29% of the company's total revenue, up 4.17% year-over-year. Belbuca generated $221.65M in revenue, accounting 35.91% of the company's total revenue, up 4.92% year-over-year. Nucynta ER generated $80.98M in revenue, accounting 13.12% of the company's total revenue, up 6.89% year-over-year. Nucynta IR generated $115.31M in revenue, accounting 18.68% of the company's total revenue, up 14.46% year-over-year.

What is Collegium Pharmaceutical’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Collegium Pharmaceutical was Belbuca. This segment made a revenue of $221.65M, representing 35.91% of the company's total revenue.